Experimental data demonstrate that GATA-3-specific DNAzymes do not lead to unspecific immune cell activation
Marburg, Germany, 27 March 2012
-
Results support favourable safety profile observed in toxicological studies and in recently completed first clinical trial of SB010
A paper published in Nucleic Acid Therapeutics (Dicke et al., 2012) found that the DNAzyme used in sterna biologicals’ drug candidate SB010, a novel inhaled GATA-3 antagonist for the treatment of moderate to severe Th2-driven asthma, does not lead to unspecific immune cell activation.